Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. Loupakis F, et al. Br J Cancer. 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0. Epub 2019 Sep 2. Br J Cancer. 2019. PMID: 31474758 Free PMC article.
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A. Santini D, et al. Among authors: loupakis f. Oncologist. 2008 Dec;13(12):1270-5. doi: 10.1634/theoncologist.2008-0181. Epub 2008 Dec 4. Oncologist. 2008. PMID: 19056857 Free article.
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. Loupakis F, et al. J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27. J Clin Oncol. 2009. PMID: 19398573
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
Loupakis F, Bocci G, Pasqualetti G, Fornaro L, Salvatore L, Cremolini C, Masi G, Danesi R, Del Tacca M, Falcone A. Loupakis F, et al. Curr Cancer Drug Targets. 2010 Feb;10(1):37-45. doi: 10.2174/156800910790980179. Curr Cancer Drug Targets. 2010. PMID: 20088795 Review.
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A. Loupakis F, et al. Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. doi: 10.1007/s00280-009-1196-1. Epub 2010 Mar 17. Cancer Chemother Pharmacol. 2010. PMID: 20237927 Clinical Trial.
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.
Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P, Sperduti I, Giannarelli D, Cognetti F. Loupakis F, et al. J Exp Clin Cancer Res. 2010 May 26;29(1):58. doi: 10.1186/1756-9966-29-58. J Exp Clin Cancer Res. 2010. PMID: 20504361 Free PMC article.
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A. Fornaro L, et al. Among authors: loupakis f. Crit Rev Oncol Hematol. 2011 Jun;78(3):243-51. doi: 10.1016/j.critrevonc.2010.06.003. Epub 2010 Jul 8. Crit Rev Oncol Hematol. 2011. PMID: 20619672
265 results